

Disclosure regarding Employees Stock Option Scheme - 2018 for the year ended 31st March 2026

A. Relevant disclosures in terms of the 'Guidance note on accounting for Employee Share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time:

Members may refer to the audited financial statements (Standalone & Consolidated) prepared as per Indian Accounting Standard (IND-AS) for FY 2026. The same is available at <https://www.unichemlabs.com/annual-report.php>

B. Diluted EPS on issue of shares pursuant to all the Schemes covered under the Regulations shall be disclosed in accordance with 'IND-AS 33-Earnings per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time:

Diluted EPS for the year ended 31st March 2026 is ₹ 22.53 (Standalone) calculated in accordance with IND-AS 33.

C. Details related to Employee Stock Option Scheme 2018 of the Company for the year ended 31st March 2026:

(i) Description of the Employee Stock Option Scheme 2018 as under:

Particulars	Scheme Details
Date of Shareholders' approval through Postal Ballot	15th May 2018
Total number of Options approved under ESOS	52,75,275
Vesting requirements	The employees shall be granted options which will be vested on the expiry ranging from 1 year to 3 years from the grant date.
Exercise price or pricing formula	The exercise price will be determined by the Nomination and Remuneration Committee (NRC) in accordance with the Scheme, at the time of grant of Options and will be detailed in the letter of grant. In any event, the Exercise Price will not be below the par value of the Equity Shares
Maximum term of Options granted	Within 15 months from the date of vesting.
Source of Shares (Primary, Secondary or combination)	Primary
Variation in terms of Options	See note below

The 1st and 2nd tranche of the exercise period was extended as per approval of the NRC meeting held on 4th August 2025, as under:

Tranche of Options	Vesting Date	Options	Current Exercise Period (within 15 months from Vesting Date)	Extended Exercise Period
1st Tranche – 50% of the Options Granted	01-07-2024	250,000	30-09-2025	30-09-2026
2nd Tranche – 25% of the Options Granted	01-05-2025	125,000	31-07-2026	30-09-2026

(ii) Method used to account for ESOS - Fair Value Method/Intrinsic:

Under IND AS, Fair value method is used for accounting.

(iii) Where the Company opts for expensing of the Options using the Intrinsic Value of the Options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the Options and the impact of this difference on profits and on EPS of the Company: Not applicable.

(iv) Option movement during the year:

Particulars	Details
Number of Options outstanding at the beginning of the period	5,00,000
Number of Options granted during the year	-
Number of Options forfeited/lapsed during the year	-
Number of Options vested during the year	1,25,000
Number of Options exercised during the year	-
Number of shares arising as a result of exercise of Options	-
Money realized by exercise of Options (INR), if scheme is implemented directly by the Company	-
Loan repaid by the Trust during the year from exercise price received	NA
Number of Options outstanding at the end of the year	5,00,000
Number of Options exercisable at the end of the year	3,75,000

(v) Weighted-average exercise prices and weighted-average fair values of Options under the Employees Stock Option Scheme - 2018 of the Company:

Particulars	Exercise Price	Fair value
Exercise price equals market price	NA	NA
Exercise price is greater than market price	NA	NA
Exercise price is less than the market price	370.00	122.00

Fair Value calculated based on Black & Scholes Option Pricing Model.

(vi) Employee wise details (name of employee, designation, number of Options granted during the year, exercise price) of Options granted during the year (excluding lapsed options):

- (a) **senior managerial personnel:** Nil
- (b) **any other employee who receives a grant in any one year of Option amounting to 5% or more of option granted during FY 2026:** Nil
- (c) **identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the Company at the time of grant:** Nil

(vii) A description of the method and significant assumptions used during the year to estimate the fair value of Options including, the weighted average values of share price, exercise price, expected volatility, expected Option life, expected dividends, the risk-free interest rate and any other inputs to the model; the method used and the assumptions made to incorporate the effects of expected early exercise, how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and whether and how any other features of the Option grant were incorporated into the measurement of fair value, such as a market condition:

The fair value of the Option has been determined using the Black Scholes Options Pricing Model. The assumptions used in this model for calculating fair value are as below:

Particulars	Details
Exercise price (₹)	370.00
Risk free interest rate (%)	7.11%
Expected life (Years)	2.52
Expected volatility (%)	48.33%
Expected dividend yield (%)	1.38%
The price of the underlying share in the market at the time of Option grant (₹)	374.60

For and on behalf of the Board of Directors,